Aurinia Pharmaceuticals (AUPH) Interest Expenses (2023 - 2026)

Aurinia Pharmaceuticals (AUPH) has 9 years of Interest Expenses data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Interest Expenses fell 98.77% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (down 104.21% YoY) and the FY2025 annual result came in at $54.1 million, down 64.99% from the prior year.
• Interest Expenses climbed to $1.0 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $92.9 million in Q2 2024 to a low of -$2.6 million in Q4 2024.
• A 5-year average of $18.5 million and a median of $1.4 million in 2024 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 142880.0% in 2024, down 977.63% in 2024.
• Tracing AUPH's Interest Expenses over 5 years: stood at $1.2 million in 2022, then slumped by 75.42% to $295000.0 in 2023, then sank by 977.63% to -$2.6 million in 2024, then increased by 15.68% to -$2.2 million in 2025, then soared by 146.36% to $1.0 million in 2026.
• The last three Interest Expenses figures came in at $1.0 million (Q1 2026), -$2.2 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.